RCM Technologies, Inc. — Form 10-Q Summary
Reporting period: The filing covers the 13 and 26 weeks ended July 1, 2023, compared with periods ended July 2, 2022. Although the request metadata says 2022 Q2, the filing itself is for 2023 Q2. Figures below are in U.S. dollars; financial amounts are in millions unless stated otherwise.
Business context
RCM provides engineering, specialty healthcare staffing, life sciences and information technology consulting and project services. Its three reportable segments are Specialty Health Care, Engineering, and Life Sciences and IT. The company says the business is cyclical and sensitive to economic conditions, customer spending and demand for staffing and consulting services.
Financial performance and liquidity
| Metric | 13 weeks ended July 1, 2023 | 13 weeks ended July 2, 2022 | 26 weeks ended July 1, 2023 | 26 weeks ended July 2, 2022 |
|---|---|---|---|---|
| Revenue | $67.0 | $74.3 | $134.2 | $156.3 |
| Gross profit / margin | $18.8 / 28.0% | $21.7 / 29.2% | $37.8 / 28.2% | $45.1 / 28.9% |
| Operating income / margin | $5.7 / 8.6% | $8.2 / 11.0% | $11.5 / 8.5% | $17.2 / 11.0% |
| Net income | $4.0 | $6.0 | $7.8 | $12.5 |
| Diluted earnings per share | $0.47 | $0.57 | $0.87 | $1.18 |
For the first half, operating cash flow was $16.5 million, down from $20.8 million a year earlier; capital expenditures were $0.6 million. Cash increased to $1.3 million from $0.3 million at December 31, 2022. At July 1, current assets were $77.1 million and current liabilities were $64.6 million, a $12.5 million excess of current assets.
Revolving-credit borrowings were $14.9 million, versus $8.8 million at year-end; additional facility availability was $28.1 million. The $45 million facility expires April 2026 and is secured by substantially all company assets and subsidiary stock. The effective weighted average borrowing rate, including unused fees, was 6.3% for the first half, compared with 1.9% a year earlier. The company reported compliance with its covenants.
Material changes versus prior-year periods
- Second-quarter revenue declined 9.8%; first-half revenue fell 14.2%. Specialty Health Care accounted for most of the decline, with first-half segment revenue down $21.0 million, attributed mainly to lower COVID-19-related demand as activity shifted from pandemic levels to endemic conditions.
- First-half operating income fell to $11.5 million from $17.2 million and net income to $7.8 million from $12.5 million. Gross margin declined 0.7 percentage points; selling, general and administrative expense fell in dollars but rose as a share of revenue.
- Engineering first-half revenue declined 3.2%, and its gross margin fell to 22.5% from 26.3%, primarily because lower utilization spread fixed salary costs over lower revenue. Life Sciences and IT revenue was broadly stable, while its gross margin improved to 37.2% from 32.6%, attributed to managed services and RPO work.
- First-half interest expense increased with higher borrowing, which the company said was used primarily to fund stock repurchases. Repurchases totaled $21.1 million for the half; 1.58 million shares were repurchased at an average $13.53 per share. The board authorized a new program of up to $25 million; $18.3 million remained available at July 1.
- First-half operating cash flow benefited by $20.8 million from the increase in net transit payables, associated with large multiyear EPC projects. The company notes these balances can fluctuate substantially; transit payables exceeded transit receivables by about $27.3 million at July 1.
Outlook, risks and unusual items
- No numerical revenue or earnings guidance is provided. Management said it believes liquidity is sufficient for at least the next 12 months and that Specialty Health Care is positioned for revenue growth, subject to seasonality and uncertainty around post-pandemic demand.
- Management identifies economic cyclicality, customer concentration and collection risk, competition and pricing pressure, employee recruiting and retention, staffing-related insurance and claims, regulation, foreign exchange, cybersecurity, and acquisition execution and financing as risks. One customer represented 18.7% of first-half revenue, all in Specialty Health Care.
- A $0.4 million gain was recorded in the first half from final collection of escrow related to the 2021 sale of Canadian Power Systems assets. This is a nonrecurring item.
- The company recorded $2.8 million for asserted claims. For a client claim concerning an Industrial Processing project, it reserved $0.5 million; the company believes damages, if any, may be contractually capped at $3.3 million and covered by insurance subject to stated terms, but gives no assurance of either limitation or coverage. Other claims could exceed accruals.
- Disclosure controls and procedures were reported ineffective at July 1, 2023 because previously identified material weaknesses in IT general controls continued, involving SAP access, segregation of duties, change management and user access. Management said the weaknesses had not caused a financial-statement misstatement and remediation was in progress, with timing uncertain.
- The company expects a financial-reporting system upgrade or replacement to go live in 2024 and estimates its cost at $0.5 million to $1.0 million.
Important facts for investors to verify
- Confirm the period: this filing is for Q2 and the first half of fiscal 2023, not 2022 Q2 as stated in the request metadata.
- Review the sustainability of Specialty Health Care revenue after the decline in pandemic-related demand, and whether Engineering utilization and margins recover.
- Assess cash conversion and working-capital quality, especially the large, project-related increase in net transit payables and the rise in accounts receivable.
- Track borrowing, interest expense, covenant headroom and further share repurchases; repurchases were funded in part by increased credit-facility borrowings.
- Monitor remediation of the material weaknesses and the timing and cost of the financial-system upgrade.
- Reconcile an apparent filing-text discrepancy: the statement of operations reports second-quarter SG&A of $12.723 million, while an MD&A table shows $12.273 million. The filing does not explain this difference.